SCHEMBL26096321

SCHEMBL26096321

O=C(NCc1ccc(NC2CCCC2)cc1Cl)c1cc(Cl)ccc1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.48
MEN1 O00255 1/20 0.48
LMNA P02545 1/20 0.48
ALPL P05186 1/20 0.48
ALPI P09923 1/20 0.48
MAPT P10636 1/20 0.48
ALOX12 P18054 1/20 0.48
HTT P42858 1/20 0.48
KMT2A Q03164 1/20 0.48
TUBB P07437 1/20 0.46
NR1H4 Q96RI1 3/20 0.45
P2RX1 P51575 3/20 0.45
TMPRSS4 Q9NRS4 1/20 0.45
CDK1 P06493 1/20 0.44
GAA P10253 1/20 0.44
SENP1 Q9P0U3 1/20 0.44
PTGS2 P35354 1/20 0.43
EPHX2 P34913 2/20 0.43
ERCC1 P07992 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23675382 0.82 ERCC1 (0.59) ALDH1A1LMNATUBBP2RX1TMPRSS4
SCHEMBL30100395 0.82 ERCC1 (0.59) ALDH1A1LMNATUBBP2RX1TMPRSS4
SCHEMBL23675432 0.81 RAB9A (0.55) ALDH1A1MEN1LMNAMAPTHTT
SCHEMBL26095655 0.80 RAB9A (0.54) ALDH1A1HPGDMEN1LMNAMAPT
SCHEMBL23675394 0.79 P2RX1 (0.69) ALDH1A1HPGDMEN1KMT2ANR1H4
SCHEMBL23675403 0.77 EPHX2 (0.55) LMNATUBBNR1H4P2RX1TMPRSS4
SCHEMBL23675437 0.77 P2RX1 (0.56) MEN1LMNAMAPTKMT2ATUBB
SCHEMBL23675431 0.76 P2RX1 (0.58) ALDH1A1MEN1LMNAMAPTHTT
SCHEMBL30100438 0.76 TMPRSS4 (0.57) ALDH1A1HPGDMEN1LMNAMAPT
SCHEMBL23685589 0.76 TMPRSS4 (0.57) ALDH1A1HPGDMEN1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) 2023-05-04 US disclosed
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) 2023-05-04 US disclosed
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING EIF2AK2, SARS1, ACE ALDH1A1 770/4885HPGD 1066/4885MEN1 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.